Results of the cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) ± bleomycin treatment and evaluation of prognostic factors in aggressive lymphomas in Turkey

Oncology (Switzerland)

Volumn 54, Issue 5, 1997, Pages 376-379

  DinÇol, Dilek ^a   Akbulut, Hakan ^a   İÇli, Fikri ^a   Samur, Mustafa ^a   Karaoguz, Handan ^a   Demirkazık, Ahmet ^a   Çay, Filiz ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

CHOP; Non Hodgkin s lymphoma; Prognostic factors

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISOLONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; DEVELOPING COUNTRY; FEMALE; HIGH RISK POPULATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; STATISTICAL ANALYSIS; SYMPTOM; TURKEY (REPUBLIC);

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TURKEY; VINCRISTINE;

EID: 1842404727     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227722     Document Type: Article

References (11)

1. Longo LD, DeVita VT, Jaffe ES, Mauch P, Urba WJ: Lymphocytic lymphomas; in DeVita VT. Heilman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology. Philadelphia, Lippincott, 1993, pp 1859-1927.
2. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993;328:1002-1006.
3. Coiffier B, Gisselbrecht C, Vose JM, Tilly H, Herbrecht R, Bosly A, Armitagc JO: Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 1991:9: 211-219.
4. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993;329:987-994.
5. Boot H, Taal BG, Burgers JMV, Van Heerde P, Hart AAM, de Jong D: Is the International Prognostic Index (IPI) for aggressive nodal lymphomas also useful in gastric malt lymphoma? Proc ASCO 1996:15:414.
6. Sarpel SC, Payday S, Tuncer I, Varinli S, Kök-sal M, Akoglu T: Non-Hodgkin's lymphomas in Turkey. Cancer 1988;62:1653-1657.
7. Dinyol DHF, Erekul S, Günel N, Karaoguz H, Demirkazik A: Primary gastrointestinal lymphomas in Turkey: A retrospective analysis of clinical features and results of treatment. J Surg Oncol 1992;51:270-273.
8. Dawson-Saunders B, Trapp RG: Biostatistics. Norwalk. Appleton & Lange, 1994.
9. Gordon LI, Harrington D, Andersen J, Colgan J, Glick J, Neiman R, Mann R, Resnick GD, Barcos M, Gottlieb A, O'Connell M: Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992;327:1342-1349.
10. Verdenk FL, Van Putten WLJ, Hagenbeek A, Schouten HC, Sonncveld P, Van Imhoff GW, Kluin-Nelemans HC, Raemaekers JMM, Van Oers RHJ, Haak HL, Schots R, Dekker AW, De Gast GC, Löwenberg B: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin’s lymphoma. N Engl J Med 1995;332:1045-1051.
11. Hoskins PJ, Ng V, Spinelli JJ, Kümo P, Connors JM: Prognostic variables in patients with diffuse large cell lymphoma treated with MA-COP-B. J Clin Oncol 1991;9:220-226.